Betrixaban: Phase III data

Top-line data from the double-blind, placebo-controlled, international Phase III APEX trial in 7,513 acutely medically ill patients showed that once-daily 80 mg oral betrixaban for 35-47

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE